Micro femoral head prosthesis in applications to collapsed femoral head necrosis in the weight-bearing dome(ARCO III):A case series with short-term follow-upOACSTPCDMEDLINE
Osteonecrosis of the femoral head(ONFH)is mainly caused by a decrease in the vascular supply to the subchondral bone of the femoral head,leading to the death of bone cells,degeneration and necrosis of the subchondral bone,and eventually collapse of the femoral head.^([1])Early and accurate diagnosis is the key to successful hip-preserving therapy,and the size/location of necrosis is the main determinant for ONFH treatment.Previous studies have shown that many hip-preserving therapies achieved satisfactory results in ONFH patients with Association Research Circulation Osseous(ARCO)I–II.When ONFH progresses to ARCO IV with clinical manifestations of osteoarthrosis,total hip arthroplasty(THA)may be the only option.
Zhongzheng Wang;Yuchuan Wang;Tianyu Wang;Yining Lu;Xiaodong Lian;Yanbin Zhu;Wei Chen;Zhiyong Hou;Yingze Zhang;
Department of Orthopaedic Surgery,Hebei Medical University Third Hospital,Shijiazhuang,Hebei 050051,China Key Laboratory of Biomechanics of Hebei Province,Shijiazhuang,Hebei 050051,ChinaDepartment of Orthopaedic Surgery,Hebei Medical University Third Hospital,Shijiazhuang,Hebei 050051,China Key Laboratory of Biomechanics of Hebei Province,Shijiazhuang,Hebei 050051,China NHC Key Laboratory of Intelligent Orthopaedic Equipment,Shijiazhuang,Hebei 050051,ChinaDepartment of Orthopaedic Surgery,Hebei Medical University Third Hospital,Shijiazhuang,Hebei 050051,China Key Laboratory of Biomechanics of Hebei Province,Shijiazhuang,Hebei 050051,China NHC Key Laboratory of Intelligent Orthopaedic Equipment,Shijiazhuang,Hebei 050051,China Chinese Academy of Engineering,Beijing 100088,China
临床医学
ARCOdiagnosisdeathhead
《Chinese Medical Journal》 2024 (006)
P.737-739 / 3
supported by the grants from the Centre Guiding Local Science and Technology Development Fund Project(Science and Technology Innovation Base Project)-Grand(No.236Z7754G);Clinical Innovation Research Team of Hebei Medical University(No.2022LCTD-B35)
评论